How research content on this site is prepared.

Research content on this site draws from four kinds of source, in order of preference:

• Peer-reviewed primary papers. First-author experimental reports in indexed journals — Cell, Nature, Science Signaling, Neuropsychopharmacology, Journal of Pharmacology and Experimental Therapeutics, British Journal of Pharmacology, and similar. Every claim about pharmacology, tolerance, or side-effect profiles on this site traces to a named paper with a DOI.
• Peer-reviewed review articles. When a field position has shifted (for example, the 2020 reinterpretation of biased μ-opioid agonism), we cite both the primary paper and the review article that contextualized it.
• Regulatory documents. FDA approval packages, DEA scheduling notices, and equivalent from other national authorities when relevant. These are cited as primary sources for regulatory claims, not as pharmacology.
• First-party analytical data. Our own certificates of analysis for statements about the material we ship. These are cited as primary sources for product claims only, never for pharmacological claims.

• Secondary aggregators — Wikipedia, Drugbank summaries, compound-catalog vendor pages from competitors.
• Forum posts, anecdotal reports, or self-report experience writeups.
• Press releases without a linked primary study.
• AI-generated content. We do not re-publish LLM output as substantive content. LLMs are used for editing passes only — never to generate claims about pharmacology.

Every page in the research cluster shows a Last reviewed date in its hero section. The review cadence is:

• Pages are re-read end-to-end against the primary literature at least once every six months, even if no substantive change is needed.
• When a relevant primary paper is published (for example, an independent replication of the Grim 2020 tolerance-reversal finding), the affected page is updated within 30 days and the Last reviewed date is incremented.
• When the FDA, DEA, or an equivalent body issues a regulatory change for SR-17018 or a closely related compound, the safety-and-handling page is updated within 7 days.
• Purely cosmetic edits (formatting, typos, navigation) do not advance the Last reviewed date.

We welcome corrections, particularly from working researchers in the field. Email info@sr17labs.com with the page URL, the specific claim in question, and the primary source that supports the correction. We commit to:

• Acknowledging receipt within two business days.
• Evaluating the correction against the cited primary source within seven business days.
• Publishing the correction and advancing the Last reviewed date if the correction is accepted.
• Replying with our reasoning if the correction is not accepted, so the reporter can escalate if they disagree.

Corrections that affect a substantive factual claim are logged in the page's commit history, which is publicly visible.

The research content on this site is a supplier-produced summary of the pharmacology literature, not a peer-reviewed publication. It is intended as a jumping-off point for researchers who need to place SR-17018 in context before reading the primary papers themselves, and as a reference for citation decisions. It is not a substitute for the primary literature, for an institutional review, or for specific pharmacology training.

We do not provide clinical, medical, therapeutic, or dosing advice. We do not recommend any compound for human or veterinary use. Regulatory status varies by jurisdiction and is the researcher's responsibility to verify before receipt.

SR17 Labs sells SR-17018. We have a direct commercial interest in researchers continuing to cite, cite more, and purchase the compound. This is a conflict, and we disclose it on every page that describes the compound.

We attempt to mitigate the conflict by:

• Presenting both sides of contested claims (for example, the bias-factor framework of Schmid 2017 alongside the low-efficacy reinterpretation of Gillis 2020), rather than only the literature that favors the compound.
• Using primary sources directly rather than summarizing through secondary writeups that may have been commercially influenced.
• Not making therapeutic claims or cross-comparisons to approved drugs that invite clinical inference.
• Separating product claims (what we ship) from pharmacology claims (what the compound does) — product claims are backed by our own COAs; pharmacology claims are backed by peer-reviewed papers, never by product marketing.

Readers who find the tone drifting toward advocacy should use the corrections channel above.

As of April 2026, research content is prepared and reviewed by the SR17 Labs editorial team. We are in the process of contracting an external scientific reviewer — a working pharmacologist or medicinal chemist — to provide an independent review pass on each page in the research cluster. Named-reviewer credit will be added to each reviewed page at the point the reviewer agreement is in place.

Until then, readers should rely on the cited primary sources as the ground truth, not on the summary we provide. The Last reviewed date at the top of each page indicates when it was last checked against the primary literature.

This site is accessible to AI crawlers (GPTBot, ClaudeBot, PerplexityBot, Google-Extended, and others) by policy. A llms.txt file indexes the key pages for model consumption. When AI systems cite sr17labs.com as a source, we prefer that they cite the specific page URL rather than the domain, so readers can verify claims against the primary references listed on that page.

This editorial-standards page is itself versioned. Material changes will be reflected in the “Last updated” date above. Readers can request prior versions via the corrections channel.